Syros Pharmaceuticals, Inc.

NasdaqGS:SYRS Stock Report

Mkt Cap: US$102.1m

We’ve recently updated our valuation analysis.

Syros Pharmaceuticals Valuation

Is SYRS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SYRS?

Other financial metrics that can be useful for relative valuation.

SYRS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does SYRS's PS Ratio compare to its peers?

The above table shows the PS ratio for SYRS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average10.6x
LVTX LAVA Therapeutics
5.8x-14.3%US$99.4m
CDTX Cidara Therapeutics
2x7.2%US$108.1m
ORTX Orchard Therapeutics
4.2x40.8%US$73.2m
FIXX Homology Medicines
28.7x64.8%US$97.1m
SYRS Syros Pharmaceuticals
4.3x63.2%US$102.1m


Price to Earnings Ratio vs Industry

How does SYRS's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a14.1%
n/an/an/a


Price to Sales Ratio vs Fair Ratio

What is SYRS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SYRS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.4x
Fair PS Ratio16.5x

Price-To-Sales vs Fair Ratio: SYRS is good value based on its Price-To-Sales Ratio (4.3x) compared to the estimated Fair Price-To-Sales Ratio (16.5x).


Share Price vs Fair Value

What is the Fair Price of SYRS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SYRS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$4.93
US$25.40
+415.2%
68.4%US$60.00US$15.00n/a5
Jan ’24US$3.59
US$27.60
+668.8%
60.7%US$60.00US$15.00n/a5
Dec ’23US$3.95
US$27.60
+598.7%
60.7%US$60.00US$15.00n/a5
Nov ’23US$4.35
US$43.40
+897.7%
32.8%US$60.00US$27.00n/a5
Oct ’23US$6.44
US$43.40
+573.9%
32.8%US$60.00US$27.00n/a5
Sep ’23US$7.87
US$84.00
+967.8%
69.3%US$190.00US$30.00n/a5
Aug ’23US$7.91
US$96.00
+1,113.0%
53.8%US$190.00US$40.00n/a5
Jul ’23US$9.10
US$130.00
+1,328.6%
31.9%US$190.00US$90.00n/a5
Jun ’23US$7.80
US$140.00
+1,694.9%
37.0%US$230.00US$90.00n/a7
May ’23US$8.42
US$158.57
+1,783.7%
32.8%US$230.00US$90.00n/a7
Apr ’23US$11.10
US$158.57
+1,328.6%
32.8%US$230.00US$90.00n/a7
Mar ’23US$13.30
US$162.86
+1,124.5%
33.1%US$230.00US$90.00n/a7
Feb ’23US$20.70
US$162.86
+686.7%
33.1%US$230.00US$90.00US$5.327
Jan ’23US$32.60
US$171.43
+425.9%
26.0%US$230.00US$90.00US$3.597
Dec ’22US$36.40
US$171.43
+371.0%
26.0%US$230.00US$90.00US$3.957
Nov ’22US$44.00
US$171.43
+289.6%
26.0%US$230.00US$90.00US$4.357
Oct ’22US$45.50
US$171.43
+276.8%
26.0%US$230.00US$90.00US$6.447
Sep ’22US$53.10
US$165.71
+212.1%
15.8%US$200.00US$130.00US$7.877
Aug ’22US$46.20
US$165.71
+258.7%
15.8%US$200.00US$130.00US$7.917
Jul ’22US$56.60
US$165.71
+192.8%
15.8%US$200.00US$130.00US$9.107
Jun ’22US$63.50
US$165.71
+161.0%
15.8%US$200.00US$130.00US$7.807
May ’22US$60.40
US$165.71
+174.4%
15.8%US$200.00US$130.00US$8.427
Apr ’22US$73.85
US$165.71
+124.4%
15.8%US$200.00US$130.00US$11.107
Mar ’22US$94.50
US$171.43
+81.4%
14.1%US$200.00US$130.00US$13.307
Feb ’22US$109.10
US$171.43
+57.1%
14.1%US$200.00US$130.00US$20.707


Discover undervalued companies